Alpha Teknova has commenced an underwritten public offering of its common stock. The life sciences reagent producer plans to use the net proceeds for general corporate purposes, including the potential repayment of outstanding debt obligations.

The proposed offering is subject to market conditions, with no assurance regarding completion, size, or terms. Teknova intends to grant underwriters a 30-day option to purchase up to an additional 15% of shares offered. All shares being sold are issued directly by the company.

Offering Details and Use of Proceeds

TD Cowen and William Blair are acting as joint book-running managers for the transaction. The securities are being offered pursuant to an effective shelf registration statement on Form S-3, previously filed with the Securities and Exchange Commission (SEC) on July 10, 2025, and declared effective on July 16, 2025.

Teknova stated it may allocate a portion of the net proceeds to acquire or invest in complementary businesses, products, and technologies. However, the company disclosed that it currently has no commitments or arrangements for such acquisitions.

Regulatory Compliance

The offering is conducted under a preliminary prospectus supplement and accompanying prospectus filed with the SEC. These documents will be available on the SEC’s website. Copies may also be obtained from TD Securities (USA) LLC or William Blair & Company, L.L.C., as specified in the filing.

The press release explicitly states that this announcement does not constitute an offer to sell or a solicitation of an offer to buy these securities in any jurisdiction where such actions would be unlawful prior to registration or qualification.

Alpha Teknova Inc and Pluristyx announced the completion of a Type II Drug Master File (DMF) for the PluriFreeze cryopreservation system. This submission to the U.S. Food and Drug Administration (FDA) aims to streamline regulatory pathways for drug makers incorporating PluriFreeze into clinical development.

Regulatory Support for Cell Therapy

The DMF provides comprehensive chemistry, manufacturing, and controls (CMC) documentation for the PluriFreeze system. Developers using PluriFreeze in preclinical stages can request a letter of authorization (LOA) from Pluristyx to cross-reference this file in their Investigational New Drug (IND) applications and Biologics License Applications (BLA). This move is designed to accelerate the development of next-generation therapies by providing a documented regulatory position for the cryopreservation media.

Stephen Gunstream, President and Chief Executive Officer of Teknova, stated that the file addresses customer needs as the cell therapy industry matures. He noted that customers require assurance that reagents can support processes from clinical development through commercialization. The DMF places this documentation on record with the FDA, enabling seamless scaling.

Product Specifications and Performance

PluriFreeze is a synthetic, animal-origin-free biopreservation media designed for scalable manufacturing of cell-based products. The system includes:

• PluriFreeze Base: A cellular wash that mimics intracellular space and provides metabolic support.
• PluriFreeze PF10: A low-viscosity freezing medium containing 10% dimethyl sulfoxide (DMSO), which simplifies scale-up and process automation.

Both components are available for research use and Good Manufacturing Practice (GMP) applications. In comparative studies against an industry reference, PluriFreeze PF10 demonstrated similar post-thaw viability, recovery, doubling times, expansion, and surface marker expression across multiple pluripotent stem cell lines and Natural Killer (NK) cells. The system remains stable for up to two years at 2-8 °C.

Strategic Collaboration

This filing builds on a collaboration announced in March 2025, where Teknova became the exclusive manufacturer and distributor of the PluriFreeze product line in the United States and Canada. Teknova contributed the necessary manufacturing and quality content to support the DMF. The products are manufactured at Teknova’s ISO 13485 certified facilities in Hollister, California.

Dr. Jason Carstens, Chief Operating Officer and Co-Founder of Pluristyx, emphasized that cryopreservation is often overlooked during process development despite being critical. He highlighted PluriFreeze’s low-viscosity formulation as a key differentiator for manufacturability and scalability.

What the Numbers Show

The completion of the Type II DMF represents a significant regulatory milestone for both companies. By securing FDA documentation for CMC details, Teknova and Pluristyx reduce the administrative burden for their clients. This allows drug developers to focus on therapeutic efficacy rather than compiling extensive regulatory data for the cryopreservation component, potentially shortening the time-to-market for advanced therapies.